Updates in anti-HER2 combination therapy.
Burstein
Harold
H
Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA 02115, USA.
D018943:Anthracyclines / Q000627:therapeutic use* / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use* / Q000633:toxicity; D004359:Drug Therapy, Combination; D006801:Humans; D018579:Patient Selection; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D043823:Taxoids / Q000627:therapeutic use* / Q000633:toxicity; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C080625:taxane